Perspective Therapeutics (CATX) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 166.0% versus a loss of 29.1%. Over five years, CATX leads with a -60.3% price change compared with -76.4% for PRLD. Prelude Therapeutics is the larger company by market cap ($305.6 million vs $280.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | PRLD |
|---|---|---|
| Share price | $2.46 | $3.83 |
| Market cap | $280.81M | $305.65M |
| 1-day change | +4.24% | +0.52% |
| YTD return | -10.55% | +32.07% |
| 1-year return | -29.11% | +165.97% |
| 5-year return | -60.32% | -76.45% |
| EPS (TTM) | $-1.33 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $6.83 |
| 52-week low | $1.96 | $1.15 |
| Distance from 52-week high | -60.06% | -43.92% |
| Average volume | 1.68M | 477.81K |
| Shares outstanding | 114.15M | 65.08M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed CATX by 195.1 percentage points over the past year.
CATX vs PRLD FAQ
Which is bigger, Perspective Therapeutics or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $305.65M compared with $280.81M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or PRLD?
PRLD returned +165.97% over the past 12 months, compared with -29.11% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.